Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 12/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184386 | 1.00 | PGR (0.65) | PGRARTRPV4SLC6A2SLC6A4 | |
| SCHEMBL3194248 | 1.00 | PGR (0.65) | PGRARTRPV4SLC6A2SLC6A4 | |
| SCHEMBL3187947 | 0.92 | PGR (0.59) | PGRARTRPV4SLC6A2SLC6A4 | |
| SCHEMBL3188688 | 0.86 | PGR (0.62) | PGRARTRPV4SLC6A2SLC6A4 | |
| SCHEMBL3177878 | 0.86 | PGR (0.62) | PGRARTRPV4SLC6A2SLC6A4 | |
| SCHEMBL15575031 | 0.85 | PGR (0.62) | PGRARTRPV4SLC6A2SLC6A4 | |
| SCHEMBL22565823 | 0.85 | PGR (0.62) | PGRARTRPV4SLC6A2SLC6A4 | |
| SCHEMBL20046664 | 0.85 | PGR (0.62) | PGRARTRPV4SLC6A2SLC6A4 | |
| SCHEMBL3193251 | 0.85 | PGR (0.55) | PGRARTRPV4SLC6A2SLC6A4 | |
| SCHEMBL15575029 | 0.85 | PGR (0.62) | PGRARTRPV4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7670613-B2 | Androgen modulators | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7670613-B2 | Androgen modulators | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7670613-B2 | Androgen modulators | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100048517-A1 | ANDROGEN MODULATORS | PFIZER INC | 2010-02-25 | — | — | US | disclosed |
| US-20100048517-A1 | ANDROGEN MODULATORS | PFIZER INC | 2010-02-25 | — | — | US | disclosed |
| US-20100048517-A1 | ANDROGEN MODULATORS | PFIZER INC | 2010-02-25 | — | — | US | disclosed |
| US-20060009427-A1 | 4-(2-Cyano-cyclohexyloxy)-2-trifluoromethyl-benzonitrlle, a salt, or an isomer;selective androgen receptor modulators; decrease excess sebum secretions; stimulafnts of hair growth at higher rates of cosmetically acceptable hair growth in patients with alopecia; acne; skin disorders; prostate cancer | WARNER-LAMBERT COMPANY LLC | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048517-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | PGR 62/4885AR 1/4885TRPV4 150/4885 |
| US-20060009427-A1 | 4-(2-Cyano-cyclohexyloxy)-2-trifluoromethyl-benzonitrlle, a salt, or an isomer;selective androgen receptor modulators; decrease excess sebum secretions; stimulafnts of hair growth at higher rates of cosmetically acceptable hair growth in patients with alopecia; acne; skin disorders; prostate cancer | AR, FSHR, MC1R | PGR 225/4885AR 1/4885TRPV4 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.